Anxiety and Depression Treatment Market Revenue To Reach $24,467.7 Million by 2030 says P&S Intelligence – About Your Online Magazine


NEW YORK, April 8, 2021 / PRNewswire / – The World Health Organization (WHO) has designated October 10º as World Mental Health Day, in order to raise awareness of these issues and decrease people’s hesitation to seek treatment. As a result of such initiatives, the global anxiety and depression treatment market the value is expected to increase from $ 17,770.9 million in 2020 for $ 24,467.7 million in 2030, at a CAGR of 3.3% between 2021 and 2030, according to the market research report published by P&S Intelligence.

PandS Intelligence

PandS Intelligence

Likewise, a program, called Better Outcomes in Mental Health Care (BOiMHC), and an organization, called the Mental Health Association, were formed to help the cause in Australia. Another organization that is helping the growth of the anxiety and depression treatment market with its support for patients and educational courses is the National Alliance on Mental Illness (NAMI), which was founded in the USA in 1979.

Main highlights of the global anxiety and depression treatment market

  • Demand for devices increases faster than for drugs

  • Expanding geriatric population is the biggest market driver

  • Increased awareness of mental health, positively affecting market growth

  • Hospital pharmacies responsible for the majority of sales of drugs and devices

  • North America largest market for drugs and devices for anxiety and depression

  • Companies launching new drugs after receiving regulatory approval

Get the sample, copy this report @ https://www.psmarketresearch.com/market-analysis/anxiety-and-depression-treatment-market/report-sample

Due to the COVID-19 pandemic, the anxiety and depression treatment market reported a negative impact. The blockages implemented around the world led to the closure of factories, which resulted in the low production of drugs and devices. In addition, restrictions on non-essential movements and international trade have led to a reduction in the supply of these products.

The largest CAGR in the anxiety and depression medication market in the coming years is expected to be witnessed in the online channel category, based on the distribution channel. Due to the convenience of shopping offered by these sites, allowing people to place orders from home, take advantage of discounts and receive home delivery, customers are switching to them.

See the detailed report with COVID-19 Impact Analysis on Anxiety and Depression Treatment Market Research Report: By product type (drugs, devices), type of disorder (major depressive disorder, OCD, phobia, PTSD), distribution channel (hospital pharmacies) , retail pharmacies Online channels, direct channels) – Global industry analysis and demand forecast for 2030 @ https://www.psmarketresearch.com/market-analysis/anxiety-and-depression-treatment-market

Currently, North America generates the highest revenue in the anxiety and depression treatment market due to the increased incidence of chronic pain, anxiety and depression, increasing awareness of mental health and the increasing number of people receiving prescriptions for medications and associated devices. In the coming years, demand for these products will increase more rapidly in Asia Pacific (APAC). The prevalence of anxiety and depression is increasing in the region due to the growth of the elderly population.

The main companies in the global anxiety and depression treatment market are Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Johnson & Johnson, AbbVie Inc., Merck & Co. Inc., Eli Lilly and Company, Sanofi, Lundbeck A / S, GlaxoSmithKline plc, Mylan NV, Glenmark Life Sciences Limited, Cipla Ltd., Lupine Limited, AstraZeneca plc, Amneal Pharmaceuticals Inc., Sun Pharmaceuticals Ltd., Sumitomo Dainippon Pharma Co. Ltd. and Intas Pharmaceuticals Ltd.

Ask questions about this report @ https://www.psmarketresearch.com/send-enquiry?enquiry-url=anxiety-and-depression-treatment-market

Browse related reports

Revenue estimate report for the complementary and alternative medicines marketGlobally, the market for complementary and alternative medicines will exhibit the fastest growth in the Asia Pacific (APAC) in the coming years. This is attributed to the increasing use of traditional medicines and therapies, the increased incidence of chronic medical conditions and the increase in the geriatric population in several APAC countries.

Sleeping Aids market revenue estimate reportHistorically, North America it was the largest share of revenue in the sleeping pills market due to the growing number of people who do not sleep properly, initiatives that are being taken by government and private organizations to raise awareness about sleep health and technological advances in related devices.

On P&S Intelligence

P&S Intelligence is a provider of market research and consulting services that address the market information needs of emerging industries around the world. Providing the pedestal of market intelligence, P&S as an entrepreneurial research and consulting company, believes in providing complete analysis of the scenario in the ever-changing market scenario, to enable companies to make informed decisions and to base their business strategies with cunning .

Contact:
Prajneesh Kumar
P&S Intelligence
Contact: + 1-347-960-6455
The e-mail: enquiry@psmarketresearch.com
Network: https://www.psmarketresearch.com

Spin-off

Spin-off

See the original content:http://www.prnewswire.com/news-releases/anxiety-and-depression-treatment-market-revenue-to-reach-24-467-7-million-by-2030-says-ps-intelligence-301264737. html

SOURCE P&S Intelligence

Paula Fonseca